| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.02 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.083 | 0.02 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.077 | 0.02 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.073 | 0.02 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.077 | 0.02 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | 0.12 | 0.02 |